Biotech Values

[DewDiligence]

Re: DNDN insider sales

>there is no requirement that the [10b5-1] plan be periodic, at least, that's news to me and the regulation does not mention it.<

The requirement that 10b5-1 sales be periodic is implicit in the language you cited; that language would make no sense if applied to singular transactions.

>Ruth Kunath's form indicates her sales were pursuant to a 10b-5 plan, and while I could be wrong, I think she sold everything at once.<

After the recent transaction, Kunath still holds 13,200 options exercisable at $1.81/sh (to be exercised and sold in subsequent 10b5-1 transactions); this is shown in the bottommost row of the Form-4 tables:

http://www.sec.gov/Archives/edgar/data/1107332/000120919107023356/xslF345X02/bos29016_bos6rk.xml

Regards, Dew